CEL-SCI Corporation (NYSE AMEX: CVM), a late-stage oncology company, has entered into definitive agreements to sell 16,000,000 shares of its common stock at a price per share of $0.36 pursuant to a registered direct offering to an institutional investor, representing gross proceeds of approximately $5.76 million.
The investor will also receive warrants to purchase 12,000,000 shares of CEL-SCI Corporation’s common stock. The warrants have an exercise price of $0.50 per share and are not exercisable for six months from the close of the transaction. The closing of the offering is expected to take place on or before Monday, January 30, 2012, subject to the satisfaction of customary closing conditions. CEL-SCI Corporation plans to use the net proceeds for CEL-SCI's general and administrative expenses and for CEL-SCI’s Phase III clinical trials involving its investigational cancer drug Multikine® (Leukocyte Interleukin, Injection)*.
The shares and warrants are being offered by CEL-SCI Corporation pursuant to an effective shelf registration statement filed with the Securities and Exchange Commission dated August 12, 2009.
Chardan Capital Markets, LLC acted as the exclusive placement agent for the transaction.This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. The shares of common stock may only be offered by means of a prospectus. Copies of the final prospectus supplement and accompanying base prospectus can be obtained from the SEC's website at http://www.sec.gov. About CEL-SCI: CEL-SCI Corporation is developing investigational products that empower immune defenses. Its lead investigational product is Multikine (Leukocyte Interleukin, Injection), currently being studied in a pivotal global Phase III clinical trial. CEL-SCI is also developing (and investigating) an immunotherapy (LEAPS-H1N1-DC) as a possible treatment for H1N1 hospitalized patients and as a vaccine (CEL-2000) for Rheumatoid Arthritis (currently in preclinical testing) using its LEAPS technology platform. The investigational immunotherapy LEAPS-H1N1-DC treatment involves non-changing regions of H1N1 Pandemic Flu, Avian Flu (H5N1), and the Spanish Flu, as CEL-SCI scientists are very concerned about the possible emergence of a new more virulent hybrid virus through the combination of H1N1 and Avian Flu, or maybe Spanish Flu. The Company has operations in Vienna, Virginia, and in/near Baltimore, Maryland.